Skip to content

Author

K. Abouzid

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Exploring conformational dynamics of the HER2 DFG-flip using machine-learning-guided metadynamics for type II inhibitor design.

Protein kinases regulate cellular proliferation and survival through tightly controlled signalling mechanisms, and their dysregulation is a major driver of cancer. Human epidermal growth factor receptor 2 (HER2) is a clinically validated kinase target, yet structural and drug-discovery efforts have largely focused on type I inhibitors binding the active DFG-in conformation. The absence of experimentally resolved structures for HER2 in the inactive DFG-out state has limited structure-based development of inactive-state type II inhibitors. Here, we employ molecular dynamics (MD) simulations coupled with machine-learning-guided well-tempered metadynamics (MetaD) to characterize the conformational landscape underlying the DFG-in to DFG-out transition in HER2. Deep learning-based collective variable was constructed by the Deep Targeted Discriminant Analysis (DeepTDA) method employing unbiased MD data from both metastable states. DeepTDA enabled efficient sampling of the DFG-flip pathway, capturing multiple recrossing events and allowing reliable estimation of the free energy difference between the two states within accessible simulation time. The inactive DFG-out conformation is found to be energetically favoured by approximately 25 kJ/mol relative to the DFG-in state, in close agreement with experimental and computational data from other apo kinases. In addition to the canonical active conformation observed crystallographically, we identify an alternative DFG-in conformer that may contribute to the low intrinsic kinase activity reported for HER2. A DFG-up intermediate conformer is also observed, resembling crystal structures reported for Aurora-A kinase. A combined covalent docking and molecular dynamics approach followed to assess the MetaD-predicted DFG-out structure for ligand binding reliability, yielding comparable predicted/experimental binding affinity. Together, these results provide a structurally grounded inactive-state HER2 model and a mechanistic framework for structure-based design of HER2 inhibitors targeting inactive kinase conformations, highlighting the applicability of deep learning CVs to systems of complex free energy landscape.

Muhammad I. Ismail, Mai Adel, Eman M. E. Dokla et al. · 0 citations
Review Open access Jul 2026

FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches

FMS-like tyrosine kinase 3 (FLT3) is a key driver of acute myeloid leukemia (AML); mutations within FLT3, specifically ITD lesions and TKD point mutations, promote proliferation and are associated with poor prognosis. Although FLT3 inhibition is central to AML therapy, resistance, particularly via D835 activation-loop variants and the F691L gatekeeper substitution, limits durability. Among the major therapeutic classes, type I inhibitors bind the active (DFG-in) conformation, whereas type II inhibitors stabilize the inactive (DFG-out) state. In contrast, irreversible covalent inhibitors target reactive cysteine residues within the kinase domain. Collectively, these approaches represent complementary therapeutic strategies with distinct resistance liabilities and structural design considerations. This review integrates structural biology with medicinal-chemistry evidence across type I, type II, irreversible, and dual-modality FLT3 inhibitors, analyzing how hinge contacts, back-pocket occupancy, and warhead placement govern activity across wild-type and mutant FLT3. We map resistance-defining residues (e.g. F691, D835, N676, N701) and design tactics to preserve potency against resistant variants. We also summarize combination therapy that augments selective FLT3 blockade and outline PROTAC approaches that induce FLT3 degradation, positioning these modalities as alternatives when single-molecule polypharmacology is constrained. Finally, we catalogue dual-target FLT3 chemotypes, highlighting examples that retain activity against F691L and D835 in cellular systems and xenografts. Overall, this review provides a section-by-section guide covering FLT3 structure and mutation hotspots, analyses of type I, type II, and irreversible inhibitors, dual-modality designs, combinations, PROTACs, and future perspectives. It links binding mode, covalent engagement, and second-target selection to recurrent resistance biology to guide more resilient FLT3-targeted therapies for high-risk AML.

Fatma M Elmenier, Eman M. E. Dokla, Nermin Samir et al. · 0 citations